drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous genetically modified CAR T-cell therapy incorporating a chlorotoxin (CLTX) tumor-targeting domain that binds the MMP2 complex on glioblastoma, with CD28 costimulation, CD3ζ signaling, and a truncated CD19 selection tag; administered locally via intracavitary/intratumoral and intraventricular catheters.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chlorotoxin
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracavitary/Intratumoral, Intraventricular
drug_mechanism_of_action
Autologous T cells engineered with a chlorotoxin (CLTX)-based CAR that binds the MMP2-associated surface complex on glioblastoma. Antigen engagement triggers CD28 costimulation and CD3ζ signaling to activate T cells and mediate targeted cytotoxic killing of tumor cells. A truncated CD19 tag enables selection/tracking; cells are delivered locoregionally (intracavitary/intratumoral and intraventricular).
drug_name
CHM-1101 CAR-T cells
nct_id_drug_ref
NCT05627323